Australia markets closed

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
42.21+0.07 (+0.17%)
At close: 04:00PM EDT
42.17 -0.04 (-0.09%)
After hours: 04:05PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close42.14
Open42.01
Bid42.17 x 200
Ask42.22 x 300
Day's range42.00 - 42.23
52-week range19.59 - 43.59
Volume790,329
Avg. volume1,419,492
Market cap7.664B
Beta (5Y monthly)1.49
PE ratio (TTM)N/A
EPS (TTM)-2.67
Earnings date01 May 2024 - 06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est43.40
  • GlobeNewswire

    Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease

    Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with placebo over 27 weeks Results demonstrate tavapadon’s potential to provide the right balance of motor control, safety and tolerability for people living with Parkinson’s disease Additional data from the trial will be presented at a future medical meeting; results from the tavapadon Phase 3 monotherap

  • Yahoo Finance Video

    AbbVie acquiring Cerevel Therapeutics in $8.7B deal

    AbbVie (ABBV) announced it is acquiring neuroscience drug developer Cerevel Therapeutics (CERE) for $45.00 per share, putting the deal value at about $8.7 billion. AbbVie Chairman and CEO Richard Gonzalez said in the announcement that the combined portfolios will present a "significant growth opportunity well into the next decade." The deal comes about a week after AbbVie announced it was acquiring cancer drugmaker ImmunoGen (IMGN) for just over $10 billion. Yahoo Finance Healthcare Reporter Anjalee Khemlani breaks down the deal.  For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

  • PR Newswire

    AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline

    AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) today announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders. The acquisition complements AbbVie's neuroscience portfolio, adding a wide range of potentially best-in-class assets that may transform standa